ASX-listed world-leader in synthetic-polymer antibiotics Recce Pharmaceuticals Ltd (ASX:RCE) updated the market about the application process for listing its stock on the Frankfurt Stock Exchange (FSE).
Here are some key highlights-
© Gepapix | Megapixl.com
- Recce Pharmaceuticals is confident that this listing will broaden the institutional and retail investor base across the EU as well as enables access to additional capital markets.
- The Frankfurt Stock Exchange is the 3rd largest exchange in Europe and 10th largest across the world.
- The Company also revealed that it has appointed DGWA as its investor and corporate relations advisor in Europe (Deutsche Gesellschaft Für Wertpapieranalyse GMBH) as its investor and corporate relations advisor in Europe.
- Recce believes that the Company meets the requirements to dual-list on FSE and will update its application progress soon.
DETAILED DISCUSSION AT: Recce Pharmaceuticals (ASX:RCE) to expand EU investor base with FSE listing